

28th July, 2025

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter ended 30th June, 2025

The presentation on unaudited Consolidated Financial Results for the quarter ended 30th June, 2025 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a

TORRENT PHARMACEUTICALS LIMITED



Q1 FY 2025-26

Revenues: Summary



Revenue: Summary

Revenues (Rs cr)	Q1 FY26	Q1 FY25	Gr%
India	1,811	1,635	11%
United States	308	259	19%
Germany	308	284	9%
Brazil	218	196	11%
Others	533	485	10%
Total	3,178	2,859	11%

